Pharmacological Mechanisms in Antipsychotic Treatment

Antipsychotic medications exert their therapeutic effects primarily through modulation of neurotransmitter systems in the brain, most notably by antagonising dopamine D2 receptors within mesolimbic pathways. Classical, or typical, antipsychotics predominantly block D2 receptors, reducing positive symptoms such as hallucinations and delusions. Atypical agents combine D2 blockade with activity at various serotonin receptors (for example 5-HT2A antagonism), which contributes both to enhanced efficacy against negative and cognitive symptoms and to a lower propensity for motor side effects. Beyond receptor blockade, emerging work emphasises the role of transporter proteins—particularly the dopamine transporter—in shaping synaptic dopamine levels and long-term responsiveness to treatment. Intracellular signalling cascades downstream of G protein-coupled receptor engagement, including changes in cyclic AMP, protein kinase activation and gene transcription, are increasingly recognised as central to both efficacy and adaptive tolerance. Adjunctive strategies that combine antipsychotic drugs with agents targeting complementary receptors or transporters may both potentiate therapeutic benefits and attenuate side-effect profiles. Advances in neuroimaging and in vivo receptor occupancy studies have refined our understanding of the thresholds of receptor engagement necessary for benefit and the spatial distribution of drug action. Overall, current pharmacological research in antipsychotic treatment seeks to balance optimal symptom control with minimisation of adverse effects by fine-tuning receptor and transporter interactions and by exploiting novel combination regimens.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacological Mechanisms in Antipsychotic Treatment publication trend

The graph below shows the total number of articles in pharmacological mechanisms in antipsychotic treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Dopamine D2 receptor: A G protein-coupled receptor subtype whose antagonism reduces psychotic symptoms.

5-HT2A receptor: A serotonin receptor whose blockade can mitigate side effects and improve cognitive outcomes.

Dopamine transporter (DAT): A presynaptic protein that clears dopamine from the synaptic cleft, influencing neurotransmitter availability.

Receptor occupancy: The proportion of target receptors bound by a drug at a given concentration, correlating with clinical efficacy.

G protein-coupled receptor (GPCR): A membrane receptor that transduces extracellular signals into intracellular responses via G proteins.

Sensorimotor gating: A neural process measured by prepulse inhibition that reflects the ability to filter out irrelevant stimuli.

Catalepsy: A state of diminished responsiveness and muscular rigidity often used as an animal model of extrapyramidal side effects.

References

1. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. Molecular Psychiatry (2018).
2. Effect of 5-HT2A receptor antagonism on levels of D2/3 receptor occupancy and adverse behavioral side-effects induced by haloperidol: a SPECT imaging study in the rat. Translational Psychiatry (2021).